Skip to main content
SpringerLink
Log in

PET/CT in Immunodeficiency Disorders

  • Chapter
  • First Online:
PET/CT in Infection and Inflammation

Part of the book series: Clinicians’ Guides to Radionuclide Hybrid Imaging ((PET/CT))

Abstract

Immunodeficiency disorders encompass a wide array of clinical conditions in which there is an aberration of one or more of the components of the immune system. These disorders may be primary or secondary to some other condition. Primary disorders usually become apparent in childhood but may present later in life. Secondary immunodeficiency disorders are more common [1, 2]. The last few decades have witnessed a steady increase in the population with immunodeficiency disorders. This is as a result of a number of factors. The high prevalence of HIV with 36.7 million infections worldwide is an important contributing factor [3]. In addition, advances in medical intervention have increased the immunocompromised population considerably. There are more patients in the posttransplant state who are on immunosuppressive therapy, more people using potent anti-cancer chemotherapy, and an increased survival of patients with hematologic disorders and malignancies [1]. Also, chronic disease such as diabetes mellitus and the use of drugs such as corticosteroids or immunosuppressant in inflammatory disease have added to the numbers. Finally, our increased understanding of underlying mechanism of immunosuppression with the discovery of new primary immunodeficiency has also contributed to this increase [1, 4].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Mortaz E, Tabarsi P, Mansouri D, Khosravi A, Garssen J, Velayati A, Adcock IM. Cancers related to immunodeficiencies: update and perspectives. Front Immunol. 2016;7:365. eCollection 2016.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Chinen J, Shearer WT. Secondary immunodeficiencies, including HIV infection. J Allergy Clin Immunol. 2010;125:S195–203.

    Article  PubMed  Google Scholar 

  3. UNAIDS. Global AIDS update 2016 UNAIDS report. http://www.who.int/hiv/pub/arv/global-aids-update-2016-pub/en/. Accessed 16 Nov 2016.

  4. Verma N, Thaventhiran A, Gathmann B, ESID Registry Working Party, Thaventhiran J, Grimbacher B. Therapeutic management of primary immunodeficiency in older patients. Drugs Aging. 2013;30:503–12.

    Article  CAS  PubMed  Google Scholar 

  5. Fishman JA. Infections in immunocompromised hosts and organ transplant recipients: essentials. Liver Transpl. 2011;17:S34–7.

    Article  PubMed  Google Scholar 

  6. Bedimo R. Non-AIDS-defining malignancies among HIV-infected patients in the highly active antiretroviral therapy era. Curr HIV/AIDS Rep. 2008;5:140–9.

    Article  PubMed  Google Scholar 

  7. Kidd EA, Grigsby PW. Intratumoral metabolic heterogeneity of cervical cancer. Clin Cancer Res. 2008;14:5236–41.

    Article  CAS  PubMed  Google Scholar 

  8. Bonnet F, Chêne G. Evolving epidemiology of malignancies in HIV. Curr Opin Oncol. 2008;20:534–40.

    Article  PubMed  Google Scholar 

  9. Powles T, Robinson D, Stebbing J, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol. 2008;27:884–90.

    Article  PubMed  Google Scholar 

  10. Shiels MS, Engels EA. Evolving epidemiology of HIV-associated malignancies. Curr Opin HIV AIDS. 2017;12(1):6–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Sathekge M, Maes A, Van de Wiele C. FDG-PET imaging in HIV infection and tuberculosis. Semin Nucl Med. 2013;43:349–66.

    Article  PubMed  Google Scholar 

  12. Poeppel TD, Krause BJ, Heusner TA, Boy C, Bockisch A, Antoch G. PET/CT for the staging and follow-up of patients with malignancies. Eur J Radiol. 2009;70:382–92.

    Article  CAS  PubMed  Google Scholar 

  13. Lee ST, Scott AM. The current role of PET/CT in radiotherapy planning. Curr Radiopharm. 2015;8:38–44.

    Article  CAS  PubMed  Google Scholar 

  14. Gallamini A, Zwarthoed C, Borra A. Positron emission tomography (PET) in oncology. Cancers (Basel). 2014;6:1821–89.

    Article  Google Scholar 

  15. Herrera FG, Prior JO. The role of PET/CT in cervical cancer. Front Oncol. 2013;3:34.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Khiewvan B, Torigian DA, Emamzadehfard S, Paydary K, Salavati A, Houshmand S, et al. Update of the role of PET/CT and PET/MRI in the management of patients with cervical cancer. Hell J Nucl Med. 2016;19(3):254–68. https://doi.org/10.1967/s002449910409.

    Article  PubMed  Google Scholar 

  17. Gallamini A, Borra A. Role of PET in lymphoma. Curr Treat Options in Oncol. 2014;15:248–61.

    Article  Google Scholar 

  18. Tateishi U. PET/CT in malignant lymphoma: basic information, clinical application, and proposal. Int J Hematol. 2013;98:398–405.

    Article  PubMed  Google Scholar 

  19. Heald A, Hoffman JM, Bartlett J, Waskin H. Differentiation of central nervous system lesions in AIDS patients using positron emission tomography (PET). Int J STD AIDS. 1996;7:337–46.

    Article  CAS  PubMed  Google Scholar 

  20. O’Doherty M, Barrington S, Campbell M, Lowe J, Bradbeer C. PET scanning and the human immunodeficiency virus-positive patient. J Nucl Med. 1997;38:1575–83.

    PubMed  Google Scholar 

  21. van de Luijtgaarden A, van der Ven A, Leenders W, et al. Imaging of HIV-associated Kaposi sarcoma. F-18-FDG-PET/CT and In-111-bevacizumabscintigraphy. J AIDS. 2010;54:444–6.

    Google Scholar 

  22. Morooka M, Ito K, Kubota K, et al. Whole-body 18F-fluorodeoxyglucose positron emission tomography/computed tomography images before and after chemotherapy for Kaposi sarcoma and highly active antiretrovirus therapy. Jpn J Radiol. 2010;28:759–62.

    Article  PubMed  Google Scholar 

  23. Vorster M, Sathekge MM, Bomanji J. Advances in imaging of tuberculosis: the role of 18F-FDG PET and PET/CT. Curr Opin Pulm Med. 2014;20:287–93.

    Article  PubMed  Google Scholar 

  24. Ankrah AO, van der Werf TS, de Vries EF, Dierckx RA, Sathekge MM, Glaudemans AW. PET/CT imaging of mycobacterium tuberculosis infection. Clin Transl Imaging. 2016;4:131–44.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Skoura E, Zumla A, Bomanji J. Imaging in tuberculosis. Int J Infect Dis. 2015;32:87–93.

    Article  PubMed  Google Scholar 

  26. Ebner L, Walti LN, Rauch A, Furrer H, Cusini A, Meyer AM, Weiler S, et al. Clinical course, radiological manifestations, and outcome of pneumocystis jirovecii pneumonia in HIV patients and renal transplant recipients. PLoS One. 2016;11:e0164320.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Kono M, Yamashita H, Kubota K, Kano T, Mimori A. FDG PET imaging in pneumocystis pneumonia. Clin Nucl Med. 2015;40:679–81.

    Article  PubMed  Google Scholar 

  28. Bleeker-Rovers CP, van der Meer JW, Oyen WJ. Fever of unknown origin. Semin Nucl Med. 2009;39:81–7.

    Article  PubMed  Google Scholar 

  29. Keidar Z, Gurman-balbir A, Gaitini D, Israel O. Fever of unknown origin: the role of 18F-FDGPET/CT. J Nucl Med. 2008;49:1980–5.

    Article  PubMed  Google Scholar 

  30. Martin C, Castaigne C, Tondeur M, Flamen P, De Wit S. Role and interpretation of FDG-PET/CT in HIV patients with fever of unknown origin: a prospective study. J Int AIDS Soc. 2012;15(Suppl 4):18107.

    PubMed Central  Google Scholar 

  31. Bleeker-Rovers C, van der Ven A, Zomer B, de Geus-Oei LF, Smits P, Corstens FH, et al. F-18-Fluorodexoyglucose positron emission tomography for visualization of lipodystrophy in HIV-infected patients. AIDS. 2004;18:2430–2.

    PubMed  Google Scholar 

  32. Sathekge M, Maes A, Kgomo M, Stolz A, Ankrah A, Van de Wiele C. Evaluation of glucose uptake by skeletal muscle tissue and subcutaneous fat in HIV-infected patients with and without lipodystrophy using FDG-PET. Nucl Med Commun. 2010;31:311–4.

    Article  CAS  PubMed  Google Scholar 

  33. Rottenberg D, Sidtis J, Strother S, Schaper KA, Anderson JR, Nelson MJ, Price RW. Abnormal cerebral glucose metabolism in HIV-1 seropositive subjects with and without dementia. J Nucl Med. 1996;37:1133–41.

    PubMed  CAS  Google Scholar 

  34. Sathekge M, McFarren A, Dadachova E. Role of nuclear medicine in neuroHIV: PET, SPECT, and beyond. Nucl Med Commun. 2014;35(8):792–6.

    PubMed  PubMed Central  Google Scholar 

  35. Yarasheski KE, Laciny E, Overton ET, Reeds DN, Harrod M, Baldwin S, Dávila-Román VG. 18FDG PET-CT imaging detects arterial inflammation and early atherosclerosis in HIV-infected adults with cardiovascular disease risk factors. J Inflamm (Lond). 2012;9:26.

    Article  CAS  Google Scholar 

  36. Subramanian S, Tawakol A, Burdo TH, Abbara S, Wei J, Vijayakumar J, et al. Arterial inflammation in patients with HIV. JAMA. 2012;308:379–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Long B, Koyfman A. The emergency medicine approach to transplant complications. Am J Emerg Med. 2016;34:2200–8.

    Article  PubMed  Google Scholar 

  38. Katabathina VS, Menias CO, Tammisetti VS, Lubner MG, Kielar A, Shaaban A, et al. Malignancy after solid organ transplantation: comprehensive imaging review. Radiographics. 2016;36(5):1390–407.

    Article  PubMed  Google Scholar 

  39. Wareham NE, Lundgren JD, Da Cunha-Bang C, Gustafsson F, Iversen M, Johannesen HH, et al. The clinical utility of FDG PET/CT among solid organ transplant recipients suspected of malignancy or infection. Eur J Nucl Med Mol Imaging. 2017;44(3):421–31. https://doi.org/10.1007/s00259-016-3564-5.

    Article  PubMed  Google Scholar 

  40. Bianchi E, Pascual M, Nicod M, Delaloye AB, Duchosal MA. Clinical usefulness of FDG-PET/CT scan imaging in the management of posttransplant lymphoproliferative disease. Transplantation. 2008;85(5):707–12.

    Article  PubMed  Google Scholar 

  41. Bodet-Milin C, Lacombe M, Malard F, Lestang E, Cahu X, Chevallier P, et al. 18F-FDG PET/CT for the assessment of gastrointestinal GVHD: results of a pilot study. Bone Marrow Transplant. 2014;49(1):131–7.

    Article  CAS  PubMed  Google Scholar 

  42. Stelljes M, Hermann S, Albring J, Köhler G, Löffler M, Franzius C, et al. Clinical molecular imaging in intestinal graft-versus-host disease: mapping of disease activity, prediction, and monitoring of treatment efficiency by positron emission tomography. Blood. 2008;111:2909–18.

    Article  CAS  PubMed  Google Scholar 

  43. Johnston PB, Wiseman GA, Micallef IN. Positron emission tomography using F-18 fluorodeoxyglucose pre- and post-autologous stem cell transplant in non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2008;41:919–25.

    Article  CAS  PubMed  Google Scholar 

  44. Sucak GT, Özkurt ZN, Suyani E, Yaşar DG, Akdemir ÖÜ, Aki Z, et al. Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival. Ann Hematol. 2011;90:1329–36.

    Article  PubMed  Google Scholar 

  45. Sauter CS, Lechner L, Scordo M, Zheng J, Devlin SM, Fleming SE, et al. Pretransplantation fluorine-18-deoxyglucose—positron emission tomography scan lacks prognostic value in chemosensitive B cell non-hodgkin lymphoma patients undergoing nonmyeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20:881–4.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Sauter CS, Matasar MJ, Meikle J, Schoder H, Ulaner GA, Migliacci JC, et al. Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. Blood. 2015;125:2579–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Gentzler RD, Evens AM, Rademaker AW, Weitner BB, Mittal BB, Dillehay GL, et al. F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma. Br J Haematol. 2014;165(6):793–800.

    Article  CAS  PubMed  Google Scholar 

  48. Valls L, Badve C, Avril S, Herrmann K, Faulhaber P, O’Donnell J, Avril N. FDG-PET imaging in hematological malignancies. Blood Rev. 2016;30:317–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Schwenzer NF, Pfannenberg AC. PET/CT, MR, and PET/MR in lymphoma and melanoma. Semin Nucl Med. 2015;45:322–31.

    Article  PubMed  Google Scholar 

  50. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–68.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Adams HJ, de Klerk JM, Fijnheer R, Heggelman BG, Dubois SV, Nievelstein RA, et al. Bone marrow biopsy in diffuse large B-cell lymphoma: useful or redundant test? Acta Oncol. 2015;54:67–72.

    Article  CAS  PubMed  Google Scholar 

  52. Lim ST, Tao M, Cheung YB, Rajan S, Mann B. Can patients with early-stage diffuse large B-cell lymphoma be treated without bone marrow biopsy? Ann Oncol. 2005;16:215–8.

    Article  CAS  PubMed  Google Scholar 

  53. Noy A, Schoder H, Gonen M, Weissler M, Ertelt K, Cohler C, et al. The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). Ann Oncol. 2009;20:508–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol. 2014;32:3048–58.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Derlin T, Bannas P. Imaging of multiple myeloma: current concepts. World J Orthod. 2014;5:272–82.

    Article  Google Scholar 

  56. Haznedar R, Aki SZ, Akdemir OU, Ozkurt ZN, Ceneli O, Yagci M, et al. Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma. Eur J Nucl Med Mol Imaging. 2011;38:1046–53.

    Article  CAS  PubMed  Google Scholar 

  57. Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118:5989–95.

    Article  CAS  PubMed  Google Scholar 

  58. Sager S, Ergul N, Ciftci H, Cetin G, Guner SI, Cermik TF. The value of FDG PET/CT in the initial staging and bone marrow involvement of patients with multiple myeloma. Skelet Radiol. 2011;40(7):843.

    Article  Google Scholar 

  59. Nanni C, Zamagni E, Celli M, Caroli P, Ambrosini V, Tacchetti P, et al. The value of 18F-FDG PET/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients. Clin Nucl Med. 2013;38:e74–e7.

    Article  PubMed  Google Scholar 

  60. Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N, et al. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy. Blood. 2013;121:1819–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Chargari C, Vennarini S, Servois V, Bonardel G, Lahutte M, Fourquet A, et al. Place of modern imaging modalities for solitary plasmacytoma: toward improved primary staging and treatment monitoring. Crit Rev Oncol Hematol. 2012;82:150–8.

    Article  PubMed  Google Scholar 

  62. Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood. 2007;110:3507–16.

    Article  CAS  PubMed  Google Scholar 

  63. Bruzzi JF, Macapinlac H, Tsimberidou AM, Truong MT, Keating MJ, Marom EM, et al. Detection of Richter’s transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med. 2006;47:1267–73.

    PubMed  Google Scholar 

  64. Rossi D. Richter’s syndrome: novel and promising therapeutic alternatives. Best Pract Res Clin Haematol. 2016;29:30–9.

    Article  PubMed  Google Scholar 

  65. Stolzel F, Rollig C, Radke J, Mohr B, Platzbecker U, Bornhauser M, et al. 18F-FDG-PET/CT for detection of extramedullary acute myeloid leukemia. Haematologica. 2011;96:1552–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Kriengkauykiat J, Ito JI, Dadwal SS. Epidemiology and treatment approaches in management of invasive fungal infections. Clin Epidemiol. 2011;3:175–91.

    PubMed  PubMed Central  Google Scholar 

  67. Ankrah AO, Sathekge MM, Dierckx RA, Glaudemans AW. Imaging fungal infections in children. Clin Transl Imaging. 2016;4:57–72.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Ichiya Y, Kuwabara Y, Sasaki M, Yoshida T, Akashi Y, Murayama S, et al. FDG-PET in infectious lesions: the detection and assessment of lesion activity. Ann Nucl Med. 1996;10:185–91.

    Article  CAS  PubMed  Google Scholar 

  69. Hot A, Maunoury C, Poiree S, Lanternier F, Viard JP, Loulergue P, et al. Diagnostic contribution of positron emission tomography with [18F]fluorodeoxyglucose for invasive fungal infections. Clin Microbiol Infect. 2011;17(3):409–17.

    Article  CAS  PubMed  Google Scholar 

  70. Bleeker-Rovers CP, Warris A, Drenth JP, Corstens FH, Oyen WJ, Kullberg BJ. Diagnosis of Candida lung abscesses by 18F-fluorodeoxyglucose positron emission tomography. Clin Microbiol Infect. 2005;11:493–5.

    Article  CAS  PubMed  Google Scholar 

  71. Sharma P, Mukherjee A, Karunanithi S, Bal C, Kumar R. Potential role of 18F-FDG PET/CT in patients with fungal infections. AJR Am J Roentgenol. 2014;203:180–9.

    Article  PubMed  Google Scholar 

  72. Miyazaki Y, Nawa Y, Nakase K, Kohashi S, Kadohisa S, Hiraoka A, et al. FDG-PET can evaluate the treatment for fungal liver abscess much earlier than other imagings. Ann Hematol. 2011;90:1489–90.

    Article  PubMed  Google Scholar 

  73. Vos FJ, Donnelly JP, Oyen WJ, Kullberg BJ, Bleeker-Rovers CP, et al. 18F-FDG PET/CT for diagnosing infectious complications in patients with severe neutropenia after intensive chemotherapy for haematological malignancy or stem cell transplantation. Eur J Nucl Med Mol Imaging. 2012;39:120–8.

    Article  CAS  PubMed  Google Scholar 

  74. Vos FJ, Bleeker-Rovers CP, Oyen WJ. The use of FDG-PET/CT in patients with febrile neutropenia. Semin Nucl Med. 2013;43:340–8.

    Article  PubMed  Google Scholar 

  75. Glaudemans AW, de Vries EF, Galli F, Dierckx RA, Slart RH, Signore A. The use of F-FDG-PET/CT for diagnosis and treatment monitoring of inflammatory and infectious diseases. Clin Dev Immunol. 2013;2013:623036.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Palestro CJ. FDG-PET in musculoskeletal infections. Semin Nucl Med. 2013;43(5):367–76.

    Article  PubMed  Google Scholar 

  77. Familiari D, Glaudemans AW, Vitale V, Prosperi D, Bagni O, Lenza A, Cavallini M, et al. Can sequential 18F-FDG PET/CT replace WBC imaging in the diabetic foot? Nucl Med. 2011;52:1012–9.

    Article  Google Scholar 

  78. Palestro CJ. 18F-FDG and diabetic foot infections: the verdict is…. J Nucl Med. 2011;52(7):1009–11.

    Article  PubMed  Google Scholar 

  79. Kagna O, Srour S, Melamed E, Militianu D, Keidar Z. FDG PET/CT imaging in the diagnosis of osteomyelitis in the diabetic foot. Eur J Nucl Med Mol Imaging. 2012;39:1545–50.

    Article  PubMed  Google Scholar 

  80. Gnanasegaran G, Vijayanathan S, Fogelman I. Diagnosis of infection in the diabetic foot using (18)F-FDG PET/CT: a sweet alternative? Eur J Nucl Med Mol Imaging. 2012;39:1525–7.

    Article  PubMed  Google Scholar 

  81. Nawaz A, Torigian DA, Siegelman ES, Basu S, Chryssikos T, Alavi A. Diagnostic performance of FDG-PET, MRI, and plain film radiography (PFR) for the diagnosis of osteomyelitis in the diabetic foot. Mol Imaging Biol. 2010;12(3):335–42.

    Article  PubMed  Google Scholar 

  82. Palestro CJ. Radionuclide imaging of musculoskeletal infection: a review. J Nucl Med. 2016;57:1406–12.

    Article  CAS  PubMed  Google Scholar 

  83. Gomes A, Glaudemans AW, Touw DJ, van Melle JP, Willems TP, Maass AH, et al. Diagnostic value of imaging in infective endocarditis: a systematic review. Lancet Infect Dis. 2016;17(1):e1–e14. https://doi.org/10.1016/S1473-3099(16)30141-4.

    Article  PubMed  Google Scholar 

  84. Gomes A, Slart RH, Sinha B, Glaudemans AW. 18F-FDG PET/CT in the diagnostic workup of infective endocarditis and related intracardiac prosthetic material: a clear message. J Nucl Med. 2016;57:1669–71.

    Article  CAS  PubMed  Google Scholar 

  85. Herrmann K, Buck AK, Schuster T, Rudelius M, Wester HJ, Graf N, et al. A pilot study to evaluate 3′-deoxy-3′-18F-fluorothymidine pet for initial and early response imaging in mantle cell lymphoma. J Nucl Med. 2011;52:1898–902.

    Article  CAS  PubMed  Google Scholar 

  86. Buck AK, Bommer M, Stilgenbauer S, Juweid M, Glatting G, Schirrmeister H, et al. Molecular imaging of proliferation in malignant lymphoma. Cancer Res. 2006;66:11055–106.

    Article  CAS  PubMed  Google Scholar 

  87. Hutchings M. Pre-transplant positron emission tomography/computed tomography (PET/CT) in relapsed Hodgkin lymphoma: time to shift gears for PET-positive patients? Leuk Lymphoma. 2011;52:15–1616.

    Article  CAS  Google Scholar 

  88. Gourni E, Demmer O, Schottelius M, D’Alessandria C, Schulz S, Dijkgraaf I, et al. PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent. J Nucl Med. 2011;52:1803–10.

    Article  CAS  PubMed  Google Scholar 

  89. Wester HJ, Keller U, Schottelius M, Beer A, Philipp-Abbrederis K, Hoffmann F, et al. Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging. Theranostics. 2015;5:618–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Philipp-Abbrederis K, Herrmann K, Knop S, Schottelius M, Eiber M, Luckerath K, et al. In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. EMBO Mol Med. 2015;7:477–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Vorster M, Maes A, Cv W, Sathekge M. Gallium-68 PET: a powerful generator-based alternative to infection and inflammation imaging. Semin Nucl Med. 2016;46(5):436–47.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, University of Pretoria and Steve Biko Academic Hospital, Pretoria, South Africa

    Alfred Ankrah & Mike Sathekge

Authors
  1. Alfred Ankrah
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mike Sathekge
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mike Sathekge .

Editor information

Editors and Affiliations

  1. Department of Nuclear Medicine, Royal Free London NHS Foundation Trust, London, United Kingdom

    Thomas Wagner

  2. Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Centre Annexe, Mumbai, India

    Sandip Basu

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ankrah, A., Sathekge, M. (2018). PET/CT in Immunodeficiency Disorders. In: Wagner, T., Basu, S. (eds) PET/CT in Infection and Inflammation . Clinicians’ Guides to Radionuclide Hybrid Imaging(). Springer, Cham. https://doi.org/10.1007/978-3-319-90412-2_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-90412-2_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-90411-5

  • Online ISBN: 978-3-319-90412-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation